Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06731218RecruitingPhase 1
A study on RGB-5088 for type 1 diabetes
This trial tests a new treatment called RGB-5088 in people with type 1 diabetes. It aims to see if the treatment is safe and if it helps control blood sugar.
Tianjin, Tianjin MunicipalityAges 18–60 - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06717932Enrolling by invitation
Long-term safety study of CS-101 injection
This study follows up with people who already received the CS-101 injection in a previous trial to check its safety and how well it works over time.
NanningAges 12–35 - NCT06726122Enrolling by invitation
Matrix Pro skin treatment study for ages 18-84
This study tests a new device called Matrix Pro that uses Profound Matrix technology to treat skin concerns. It aims to see if the treatment is safe and works well for people with different skin types.
Amsterdam, EKAges 18–84 - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Los Angeles, CaliforniaAges 18 years+ - NCT06721494RecruitingPhase 2
A single-dose study of CS-1103 for methamphetamine use
This trial tests a single dose of an investigational drug, CS-1103, to see if it is safe and effective for people who use methamphetamine. It may help understand how the drug affects methamphetamine in the body.
Glendale, CaliforniaAges 18–55 - NCT06717412Recruiting
Low-dose conbercept for retinopathy of prematurity
This trial tests whether a low dose of conbercept, given as an eye injection, can safely treat type 1 ROP (an eye disease in premature babies). The goal is to stop abnormal blood vessel growth and prevent vision loss.
Xi'an, ShaanxiAges Any age - NCT06219239Recruiting
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.
Tianjin, Tianjin MunicipalityAges 3–35 - NCT06224257RecruitingPhase 2
Linperlisib for relapsed or refractory T-LGLL
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
Hefei, AnhuiAges 18 years+ - NCT06715501Enrolling by invitation
Testing cadonilimab with chemo and radiation for advanced esophageal cancer
This trial tests a new drug (cadonilimab) combined with standard chemotherapy and radiation for people with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this combination works better than current treatments.
Ningbo, ZhejiangAges 18–75 - NCT06712355RecruitingPhase 3
Testing an experimental drug with chemo for newly diagnosed extensive-stage small cell lung cancer
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
Tucson, ArizonaAges 18 years+ - NCT06712823RecruitingPhase 2
Long-term safety study of atumelnant for adrenal hyperplasia
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
Minneapolis, MinnesotaAges 16–74 - NCT06715891RecruitingPhase 3
Raphamin for colds in children ages 3 to 12
This trial tests if Raphamin can safely treat common cold symptoms in children. It is for kids who have had cold symptoms for less than 24 hours and have a fever of at least 100°F with other symptoms like stuffy nose or sore throat.
GatchinaAges 3–12 - NCT06711887RecruitingPhase 3
Long-term extension study of ianalumab for lupus nephritis
This study is a follow-up for people with lupus nephritis who already completed a 144-week treatment course with ianalumab in an earlier study. It tests whether continuing or stopping the drug is safe and effective over the long term.
Orchard Park, New YorkAges 18–100 - NCT05532943RecruitingPhase 1/Phase 2
Cord stem cell treatment for people with multiple sclerosis
This Phase 1/2 trial studies whether donated umbilical cord stem cells are safe and can improve multiple sclerosis. It aims to see if the treatment is workable for people who still have active MS despite standard therapies.
Taichung, Non-USAges 20–65 - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06711146RecruitingEarly Phase 1
CAR T-cell therapy for active lupus
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18 years+ - NCT06713382RecruitingPhase 2
Saline rinse for trapped lung infections
This trial tests if adding a simple saltwater rinse to standard chest tube drainage helps clear stubborn lung infections. It might be an option if you have an infected fluid pocket in your chest that isn't draining well.
Boston, MassachusettsAges 18 years+ - NCT06364553Recruiting
Metal stent for swallowing problems from cancer
This study tests whether a metal tube (stent) placed in the esophagus can safely improve swallowing in people whose cancer blocks the food pipe and cannot be cured. It may help you eat and drink more comfortably.
Rotterdam, South HollandAges 18 years+ - NCT05613985Recruiting
Ultrasound light added to usual care for infected diabetic foot ulcers
This trial tests whether adding the VULNOFAST Plus/VULNOLIGHT system to usual care can heal infected diabetic foot ulcers more safely and effectively. It compares the added treatment plus usual care versus usual care alone.
ArezzoAges 18 years+ - NCT06356688RecruitingPhase 2
Study of chemo plus immunotherapy before surgery for esophageal cancer
This trial tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (cadonilimab) given before surgery for advanced esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Nanjing, JiangsuAges 18–75 - NCT06697301RecruitingPhase 2/Phase 3
New drug with pembrolizumab for advanced melanoma
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Chandler, ArizonaAges 18 years+ - NCT06695897Recruiting
Long-term real-world study of Dupilumab for eosinophilic esophagitis
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
Aschaffenburg, BavariaAges 12 years+ - NCT06699121RecruitingPhase 2
Testing LB-P8 for people with primary sclerosing cholangitis
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Sacramento, CaliforniaAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.